advertisement-vertical Download Proto magazine app
Social Icons

Harry Campbell


In 2010, some 1.6 million Americans were diagnosed with cancer. Each case is individual: Molecular characteristics may differentiate, say, one lung tumor from another. Long known for innovations in surgery and radiation, cancer researchers at Massachusetts General Hospital are now helping to pioneer treatments in which physicians base decisions on whether a tumor has a molecular bull’s-eye of genetic mutations that a new type of drug can target. MGH scientists showed that lung cancer treatments could be personalized in this way, and they’re finding that targeted therapies work for many melanomas and a growing roster of other cancers.

Protomag on Facebook Protomag on Twitter